Companies
Vivici
the Delft-based precision-fermentation company backed by Fonterra and DSM-Firmenich launched Vivitein LF in the United States in 2026 with self-affirmed GRAS status (February 2026) and, in June 2026,…
- Country
- Netherlands
FDA GRAS (self-affirmed Feb 2026)
EU EIC €12.5M grant (Jun 2026)
Coverage
| CN | EU | US | |
|---|---|---|---|
| food-alt-protein | ✓ | ✓ | ✓ |
Regulatorsfdaefsa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Founded | 2022 | caplight.com |
| Funding | $48.6 million total funding, including Series A and a €12.5 million EIC Accelerator grant | agfundernews.com |
| Headcount | 35 employees | caplight.com · rivadata.com |
| Headquarters | Delft and Oegstgeest, Netherlands | vivici.com |
| Revenue | $400,000 annual revenue | rivadata.com |
| Regulatory approval | self-affirmed GRAS for Vivitein LF in the United States (February 2026) | cultivated-x.com · greenqueen.com.hk · nutraingredients.com · vivici.com |
| Production site | European co-manufacturing partners and Liberation Bioindustries (Indiana, US) | agfundernews.com · greenqueen.com.hk |
Independent sources: agfundernews.com · caplight.com · cultivated-x.com · greenqueen.com.hk · nutraingredients.com · rivadata.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Precision-fermented infant formula | food-alt-protein | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.